ArticleCureus2025
A Case of Rapidly Progressive Pneumonitis Induced by Nivolumab in Metastatic Gastroesophageal Adenocarcinoma: Challenges in Diagnosis and Management.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors like nivolumab have transformed cancer therapy but are associated with immune-related, sometimes life-threatening, adverse events, including pneumonitis. We report a case of a 55-year-old man with metastatic gastroesophageal adenocarcinoma who developed rapidly progressive pneumonitis within a week of initiating nivolumab and FOLFOX therapy (folinic acid, 5-fluorouracil and oxaliplatin). Despite some initial improvement with antibiotics and ongoing oral steroids, the patient deteriorated rapidly and died. This case highlights the importance of early recognition and aggressive management of immune-related pneumonitis. Clinicians must be aware of such adverse events, maintain a high index of suspicion and adopt a multidisciplinary approach to optimize outcomes, especially given the often subtle and rapidly evolving clinical presentation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.